Abstract
Current diagnostic approaches for primary cervical cancer screening, work-up of equivocal or positive screening results or follow- up after treatment of precancerous lesions primarily rely on the morphologic interpretation of squamous epithelial cells (Pap cytology), in some setting accompanied by the detection of human papillomavirus DNA and have largely contributed to remarkable reduction of disease incidence in countries with implemented screening programs. However, these approaches are limited by a poor sensitivity and reproducibility of Pap cytology and low specificity for high grade cervical intraepithelial neoplasia of HPV DNA detection assays. Early detection might be improved by complementing or even replacing these tests by markers which are more directly related to molecular events triggering HPV-induced carcinogenesis and thereby might deliver more accurate diagnostic performance. The delineation of molecular changes which occur during different stages of HPV infections and the identification of changes which induce neoplastic alterations allow for the detection of markers that specifically highlight the transforming stage of the infection where viral oncogenes are overexpressed and therefore allow for a more specific diagnosis of lesions that require treatment. The evaluation of such markers in clinical studies revealed that some indeed show an improved diagnostic performance compared to Pap cytology or HPV DNA tests only.
Keywords: Cervical cancer, human papillomavirus, diagnostics, cytology, biomarkers, p16INK4a, precancerous lesions, neoplasia, HPV-induced carcinogenesis, Pap cytology
Current Pharmaceutical Design
Title:Diagnostic Tests for the Detection of Human Papillomavirus-associated Cervical Lesions
Volume: 19 Issue: 8
Author(s): Miriam Reuschenbach and Magnus von Knebel Doeberitz
Affiliation:
Keywords: Cervical cancer, human papillomavirus, diagnostics, cytology, biomarkers, p16INK4a, precancerous lesions, neoplasia, HPV-induced carcinogenesis, Pap cytology
Abstract: Current diagnostic approaches for primary cervical cancer screening, work-up of equivocal or positive screening results or follow- up after treatment of precancerous lesions primarily rely on the morphologic interpretation of squamous epithelial cells (Pap cytology), in some setting accompanied by the detection of human papillomavirus DNA and have largely contributed to remarkable reduction of disease incidence in countries with implemented screening programs. However, these approaches are limited by a poor sensitivity and reproducibility of Pap cytology and low specificity for high grade cervical intraepithelial neoplasia of HPV DNA detection assays. Early detection might be improved by complementing or even replacing these tests by markers which are more directly related to molecular events triggering HPV-induced carcinogenesis and thereby might deliver more accurate diagnostic performance. The delineation of molecular changes which occur during different stages of HPV infections and the identification of changes which induce neoplastic alterations allow for the detection of markers that specifically highlight the transforming stage of the infection where viral oncogenes are overexpressed and therefore allow for a more specific diagnosis of lesions that require treatment. The evaluation of such markers in clinical studies revealed that some indeed show an improved diagnostic performance compared to Pap cytology or HPV DNA tests only.
Export Options
About this article
Cite this article as:
Reuschenbach Miriam and von Knebel Doeberitz Magnus, Diagnostic Tests for the Detection of Human Papillomavirus-associated Cervical Lesions, Current Pharmaceutical Design 2013; 19 (8) . https://dx.doi.org/10.2174/1381612811319080002
DOI https://dx.doi.org/10.2174/1381612811319080002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stilbenes and Xanthones from Medicinal Plants as Potential Antitumor Agents
Current Bioactive Compounds Exploration of Chemopreventive Potential of Linalool in Targeting Lung Cancer Biomarkers
Endocrine, Metabolic & Immune Disorders - Drug Targets Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Chemopreventive and Chemotherapeutic Potential of Curcumin in Breast Cancer
Current Drug Targets Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer
Current Gene Therapy Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Current Medicinal Chemistry A New Approach for β-cyclodextrin Conjugated Drug Delivery System in Cancer Therapy
Current Drug Delivery Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Effect of PUFAs Oral Administration on the Amount of Apoptotic Caspases Enzymes in Gastric Cancer Patients Undergoing Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry In Vitro Cytotoxic Activities of Platinum(II) Complex with 1-Methyl-2-(3'- hydroxypropyl)benzimidazole and 2-(3'-Hydroxypropyl)benzimidazolium Hexa- and Tetrachloroplatinate Salts
Letters in Drug Design & Discovery Obesity-Driven Inflammation and Colorectal Cancer
Current Medicinal Chemistry Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry Intranasal Fluorescent Nanocrystals for Longitudinal <i>In Vivo</i> Evaluation of Cerebral Microlesions
Pharmaceutical Nanotechnology Three Amino Acid Derivatives of Valproic Acid: Design, Synthesis, Theoretical and Experimental Evaluation as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives
The Natural Products Journal Regulatory Role of the α7nAChR in Cancer
Current Drug Targets Recent Studies and Biological Aspects of Substantial Indole Derivatives with Anti-cancer Activity
Current Organic Chemistry Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued)